Xbrane Biopharma AB

XBRANE.ST · Health Technology · Biotechnology · SE

92 employees · xbrane.com

About

Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm and currently employs 92 full-time employees. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Annual results

Reported figures, SEK · revenue down 23.2% in 2025

YearRevenueNet incomeNet marginFree cash flow
2025152M127M83.6%—
2024198M-266M-134.3%—
2023238M-388M-163.0%—
202257.0M-172M-301.8%—
202111.0M-191M-1736.4%—

XBRANE.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Xbrane Biopharma AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Xbrane Biopharma AB (XBRANE.ST) — company profile and financials · MarketPulse